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Background: Identifying effective therapy for recalcitrant chronic rhinosinusitis
with nasal polyposis (CRSwNP) is a major challenge; and subtypes such as
aspirin-exacerbated respiratory disease (AERD) are even more difﬁcult to treat.
Evidence on topical antibiotics use in (CRSwNP) is lacking. Current consensus
guidelines recommend against its routine use, but recent reviews show some
beneﬁt when managing recalcitrant disease after endoscopic sinus surgery
(ESS).
Objective: Evaluate the effect of culture-directed topical antibiotics on
sinonasal outcomes in AERD patients with a positive perioperative sinonasal
bacterial culture who have undergone ESS.
Methods: A retrospective cohort study of AERD patients with positive sinonasal
culture, who underwent ESS from 2016 to 2021 was performed. Forty-four
patients were identiﬁed and stratiﬁed based on their postoperative medical
treatment. Twenty-six underwent postoperative intranasal corticosteroids
(INCS) alone, while eighteen underwent INCS plus a 4-weeks treatment with
topical antibiotics. SNOT-22 and Lund-Kennedy score (LKS) were assessed
preoperatively and at 4-weeks and 4-6 months after ESS.
Results: A statistically signiﬁcant improvement in the 4-weeks and 4-6 months
postoperative SNOT-22 and LKS were noted within both groups (p<0.05).
However, only a statistically signiﬁcant difference was found in the 4-weeks
postoperative LKS when comparing between treatment groups (p=0.01). Our
linear regression model demonstrated a relationship between the use of
combined therapy with INCS and topical antibiotics and the LKS 4-weeks
post ESS (p=0.015).
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Conclusion: In AERD patients with a conﬁrmed sinus infection, the
combination of culture-directed topical antibiotics and intranasal
corticosteroid irrigations in the postoperative period can provide a shortterm improvement in endoscopic scores.
KEYWORDS

topical therapy for chronic rhinosinusitis, AERD, sinonasal rinses, culture, clinical
outcomes, endoscopic sinus surgery (ESS), chronic sinusitis with nasal polyps

Introduction

75% remission at 4-months after surgery (Maniakas et al., 2020).
Focusing therapy on clearing perioperative infections in the
initial postoperative period may alter the deleterious impact
that bacterial pathogens have on the regeneration of epithelium
and repopulation of the microbiome. Targeted therapy with
topical antibiotics offers several beneﬁts, including the reduction
of possible systemic side effects and potential direct treatment of
bioﬁlms (Harvey and Schlosser, 2009).
Although topical antibiotics have been considered helpful in
some settings of recalcitrant disease, its use is currently not
recommended by the most recent International Consensus
Statement on Allery and Rhinology (ICAR) on CRS and the
European Position Paper on Rhinosinusitis and Nasal Polyps
2020 (EPOS2020) (Singhal et al., 2010; Singhal et al., 2011;
Rudmik et al., 2013; Orlandi et al., 2016; Kim and Kwon, 2016).
The studies considered in the recommendation did not
speciﬁcally look at patients with CRSwNP or any of its
subtypes. Speciﬁcally, of the current studies evaluating the use
of topical antibiotics, none have explicitly looked at AERD
patients (Sykes et al., 1986; Desrosiers and Salas-Prato, 2001;
Videler et al., 2008; Shikani et al., 2013; Bonﬁls et al., 2015);
therefore, we hope to add to the current body of literature by
investigating the effect of this therapy in one of the most
challenging patient populations to treat. We aim to evaluate
the postoperative sinonasal outcomes in culture-positive AERD
patients who received a combination of topical antibiotic and
steroid irrigation versus those who received topical steroid
irrigation alone.

Aspirin exacerbated respiratory disease (AERD) is a chronic
inﬂammatory condition of the upper respiratory system (Samter
and Beers, 1967; Samter and Beers, 1968). The pathophysiology
of this condition involves an increase in the number of
inﬂammatory cells and dysregulation in the synthesis of
eicosanoids, leukotrienes, and prostaglandins (Laidlaw and
Boyce, 2013). Clinically, AERD is associated with a high rate
of nasal polyps recurrence and recalcitrant symptoms after
endoscopic sinus surgery (ESS) (Walgama and Hwang, 2017).
Recalcitrant chronic rhinosinusitis (CRS) has been
associated with the persistence of bacterial infections
(bioﬁlms), bacterial superantigens, immunodeﬁciency, and
allergens, among others. While we currently do not have a
clear understanding of how these factors affect the
pathogenesis of CRS, there is evidence that persistent bacterial
infections, such as those caused by Staphylococcus aureus
(S. aureus), have an effect on the innate immune system. This
immune response leads to an increase in the production of
interleukin (IL)-4, IL-5, and IL-13, with a subsequent increase in
immunoglobulin-E (IgE) and eosinophilia (Vickery et al., 2019).
AERD patients have an increased level of antistaphylococcal
enterotoxin IgE compared to those patients with aspirin tolerant
chronic rhinosinusitis with nasal polyps (CRSwNP). This
increased production of IgE leads to worsening eosinophil
degradation and potential worsening effect on endoscopy and
symptom scores (Vickery et al., 2019). We believe that the
combined proinﬂammatory properties of bacterial infections
and AERD make this a unique and important population
to study.
Several studies have shown that the presence of bacterial
bioﬁlms has a negative impact on the healing process after ESS
leading to persistence of postoperative symptoms and mucosal
inﬂammation (Bendouah et al., 2006; Psaltis et al., 2008; Singhal
et al., 2011). A recent study looking at the contribution of
microbes in early disease recurrence after ESS found that
perioperative positive culture with S. aureus was associated
with poor outcomes, and that clearance of the bacteria led to
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Methods
Patients
This study was approved by the Institutional Review Board
(IRB 19-009794). Patients diagnosed with AERD who
underwent ESS from 2016 to 2021 and had a positive
sinonasal culture taken preoperatively or intraoperatively, were
retrospectively identiﬁed. Patients underwent sinonasal bacterial
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topical antibiotics on sinonasal outcomes. 2.) The effect of
concurrent oral antibiotics regimen during the topical
antibiotic therapy on both sinonasal outcomes. A p-value <.05
was considered statistically signiﬁcant.

culture due to severity of symptoms and per surgeon’s
discretion. Patients were analyzed based on whether they used
topical antibiotics in the immediate postoperative period or not.
One group received postoperative intranasal corticosteroids
(INCS) only (Budesonide respule 0.5mg/2ml in 240ml saline,
B.I.D), while the other group included patients who received
combined therapy with INCS (Budesonide respule 0.5mg/2ml in
240ml saline, B.I.D) and topical antibiotic irrigation. Topical
antibiotics were prescribed twice daily for a 4-weeks period. The
type of topical antibiotic prescribed was based on culture and
susceptibility results and included tobramycin (20mg capsule/
240ml saline), mupirocin (2% ointment), and gentamicin (20mg
capsule/240ml saline).
Patient records were reviewed for the following clinical
characteristics: demographics, surgical history, and
comorbidities. Results of sinonasal cultures and sinonasal
outcomes were collected and placed in the RedCap project.

Results
Patients
A total of 44 patients met the criteria for this study. The mean
age among the overall cohort was 53 ( ± 14) with a 1.2:1 female/
male ratio. Twenty-six patients received postoperative INCS only,
while eighteen received combined therapy with INCS and topical
antibiotics. Twenty-eight patients (63.6%) had a history of
previous ESS. No differences were observed between the groups
regarding gender, age, history of asthma, allergic rhinitis, smoking,
and culture results (p>0.05). S. aureus was the most isolated
pathogen, followed by Pseudomonas. When collecting the
clinical information, we noted that all patients from the INCS
only group received an empiric oral antibiotic regimen for two
weeks as part of the postoperative treatment. In comparison, only
six patients from the INCS and topical antibiotics group received a
concurrent culture-directed oral antibiotic regimen. Prescribed
oral antibiotic agents included levoﬂoxacin, doxycycline, and
trimethoprim/sulfamethoxazole (Table 1).

Sinonasal Outcomes
The 22-item sinonasal outcome test (SNOT-22)
questionnaire assesses patients’ symptoms with 22 different
questions involving ﬁve different domains: rhinologic
symptoms, extranasal rhinologic symptoms, ear/facial
symptoms, sleep function, and psychological function
(DeConde et al., 2014). The Lund-Kennedy endoscopic score
(LKS) measures ﬁve endoscopic characteristics, including the
presence of polyps, mucosal edema, sinonasal secretions,
scarring, and crusting (Lund and Kennedy, 1997). Patients
were asked to ﬁll out the SNOT-22 questionnaire in the
preoperative visit and at each postoperative follow-up.
Additionally, the LKS was calculated at the preoperative and
each postoperative visit according to the endoscopic ﬁndings.
Data from the preoperative visit, 4-weeks, and 4-6 months
postoperative were collected and analyzed for the purposes of
this study. The previously reported minimal clinically important
difference (MCID) for SNOT-22 of 8.9 points was used to
evaluate clinically signiﬁcant improvement over time
(Chowdhury et al., 2017).

TABLE 1 Demographic and Clinical Data of the Study Population.

Characteristics

n = 44

Gender, No. (%), female

26 (59.1)

Mean age, y (SD)

53 (14)

Isolated Bacteria
Staphylococcus aureus, No, (%)

19 (43.2)

Pseudomonas aeruginosa, No, (%)

7 (15.9)

Other pathogens

Statistical Analysis

- Propionibacterium acnes, No, (%)

4 (9.1)

- Streptococcus pneumoniae, No, (%)

4 (9.1)

- Haemophilus inﬂuenza, No, (%)

3 (6.8)

- Coagulase-negative staphylococci, No, (%)

3 (6.8)

- Prevotella

2 (4.5)

- Serratia rubidaea, No, (%)

1 (2.3)

- Enterobacter Aerogenes, No, (%)

1 (2.3)

Topical antibiotic agent

Statistical analysis was performed on SPSS software (version
25.0, IBM. Corp, Armonk, NY). Standard descriptive statistics
were obtained and presented as percentages, mean ± standard
deviations (SD). After conﬁrming the normal distribution of the
data, a Student’s t-test was performed to compare the means of
each sinonasal outcome over time within and between groups.
Additionally, a linear regression model was used with
preoperative SNOT-22 and LKS scores as ﬁxed factors in the
analysis and aimed to evaluate: 1) The effect of postoperative
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- Tobramycin, No, (%)

14 (77.7)

- Mupirocin, No, (%)

3 (16.7)

- Gentamicin, No, (%)

1 (5.6)

Comorbidities

03

Asthma, No. (%)

37 (84.1)

Allergic Rhinitis, No. (%)

23 (52.3)

Obesity, No. (%)

18 (40.9)

Smoking, No. (%)

12 (27.2)
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FIGURE 1

(A). Change over time in sinonasal outcome test (SNOT-22). (B). Change over time in Lund-Kennedy endoscopic score (LKS).

Sinonasal Outcomes

For the INCS only group, a signiﬁcant difference was found
between preoperative and 4-weeks postoperative mean SNOT22 [57 vs 21.1, (p=0.006)], and between preoperative and 4-6
months postoperative mean SNOT-22 [57 vs 19.3, (p=0.001)].
The change in SNOT-22 at 4-weeks and 4-6 months met the
MCID threshold. A statistically signiﬁcant difference was found
between the mean preoperative and the postoperative LKS at
both 4-weeks [6.5 vs 4, (p=0.017)] and 4-6 months postoperative
scores [6.5 vs 3, (p=0.0001)].

As outlined in Figure 1, sinonasal outcomes were collected
and compared over time and between groups. There was no
statistically signiﬁcant difference in mean SNOT-22 between the
two groups at any point in the study. However, a statistically
signiﬁcant difference in the 4 weeks postoperative LKS was
found between them, as the INCS only group had a lower LKS
(p-value=0.01). (Tables 2, 3).

TABLE 2 Changes over time on sinonasal outcome test (SNOT-22) in the control and intervention groups (mean, S.D.).

SNOT-22
Intranasal corticosteroids
(INCS) group

Intranasal corticosteroids (INCS) + topical
antibiotic group

Comparison between groups
(p-value)

Preoperative

57 ± 24.9

54.5 ± 25

0.79

4-weeks
postoperative

21.1 ± 18.6a

19.5 ± 11.9b

0.84

4-6 months
postoperative

19.3 ± 11.8c

20.3 ± 16.2d

0.89

a

p-value between preoperative and 4-weeks postoperative in the INCS group = 0.006.
p-value between preoperative and 4-weeks postoperative in the INCS + topical antibiotic group = 0.004.
p-value between preoperative and 4-6 months postoperative in the INCS group = 0.001.
d
p-value between preoperative and 4-6 months postoperative in the INCS + topical antibiotic group = 0.029.
b
c
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TABLE 3 Changes over time on Lund-Kennedy endoscopic score (LKS) in the control and intervention groups (mean, S.D.).

LKS
Intranasal corticosteroids
(INCS) group

Intranasal corticosteroids (INCS) + topical
antibiotic group

Comparison between groups
(p-value)

Preoperative

6.5 ± 2.8

8.1 ± 3

0.10

4-weeks
postoperative

4 ± 2a

6 ± 3b

0.01

4-6 months
postoperative

3 ± 3c

4 ± 2d

0.32

a

p-value between preoperative and 4-weeks postoperative in the INCS group =0.017.
p-value between preoperative and 4-weeks postoperative in the INCS + topical antibiotic group = 0.046.
c
p-value between preoperative and 4-6 months postoperative in the INCS group = 0.0001.
d
p-value between preoperative and 4-6 months postoperative in the INCS + topical antibiotic group =0.01.
b

In the topical antibiotic and INCS group, the postoperative
mean SNOT-22 showed a sequential improvement over time.
The change in SNOT-22 was statistically signiﬁcant between the
preoperative visit and 4-week postoperative visit [54.5 vs 19.5,
(p=0.004)], and between preoperative and 4-6 months
postoperative mean SNOT-22 [54.5 vs 20.3, (p=0.029)]. The
change in SNOT-22 at 4-weeks and 4-6 months met the MCID
threshold. A statistically signiﬁcant difference was found
between the mean preoperative LKS at both 4-weeks [8.1 vs
6,(p=0.046)] and 4-6 months postoperative scores [8.1
vs 4, (p=0.01)].

SNOT-22 (p=0.84, and p=0.88), and on the 4-6 months
postoperative LKS (p=0.32) (Table 4). Regarding the impact of
concurrent therapy with oral antibiotic regimens in a portion of
our patients, our linear regression model did not show any effect
on the 4-weeks postoperative SNOT-22 (b=-8.7 [CI95%: -26 to
8.5] p=0.30) and 4-6 months postoperative SNOT-22 (b=11.9
[CI 95%:-16 to 40] p=0.37). Additionally, no statistically
signiﬁcant effect on the 4-weeks postoperative LKS (b=-0.25
[CI95%: -0.84 to 0.32] p=0.37) and the 4-6 months postoperative
LKS (b=-0.002 [CI95%: -1.0 to 1.0] p=0.99) was found.

Linear Regression

Discussion

When analyzing the impact of the postoperative use of
topical antibiotics, our linear regression model found a
positive effect on the 4-weeks postoperative LKS (b= 2.0 [CI
95%: 0.43 to 3.7] p=0.015). However, it failed to demonstrate a
detectable effect on the 4-weeks or 4-6 months postoperative

There is limited information about the effects of topical
antibiotic irrigations in patients with CRSwNP. There is even
less data on the effect of this medication therapy in patients with
AERD. To our knowledge, this is the ﬁrst study to look at the
effect of topical antibiotics, speciﬁcally in the subset of patients

TABLE 4 Linear regression analysis of the effect of postoperative topical antibiotics on sinonasal outcomes over time.

b value

Standard Error

(95% CI)

p-value

-1.6

7.9

(-18.8 to 15.5)

0.84

2.0

0.79

(0.43 to 3.7)

0.015

0.9

6.4

(-12.6 to 14.6)

0.88

0.85

0.84

(-0.88 to 2.5)

0.32

4-weeks after treatment
SNOT-22
Postoperative topical antibiotic therapy

LKS*
Postoperative topical antibiotic therapy

4-6 months after treatment
SNOT-22
Postoperative topical antibiotic therapy

LKS*
Postoperative topical antibiotic therapy

LKS, Lund-Kennedy endoscopic score; SNOT-22, Sinonasal outcome test.
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planktonic form (Jervis-Bardy et al., 2011; Boase et al., 2013).
A small number of animal and in-vitro studies have looked at the
effect of topical antibiotics on S. aureus and Pseudomonas
bioﬁlms. Many of these studies found a signiﬁcant reduction
in bioﬁlm surface area, with 90% eradication reported in one
study (Chiu et al., 2007; Ha et al., 2008; Le et al., 2008).
Several studies looking at the effect of topical antibiotics
included patients who received concurrent oral antibiotics
(Jervis-Bardy et al., 2012; Ezzat et al., 2015; Shikani et al.,
2018). These studies did not ﬁnd an impact with the use of
oral antibiotics. Given the potential for confounding results, we
wanted to conﬁrm that the use of concurrent oral antibiotics did
not affect our study. Our linear regression model found that the
use of a concurrent oral antibiotic regimen in those patients with
prescribed topical antibiotic therapy had no effect on short-term
and long-term sinonasal outcomes. The lack of effect by the
addition of oral antibiotics is expected as previous studies
looking at the use of oral antibiotics alone for acute
rhinosinusitis only showed a slight beneﬁt over placebo
(Orlandi et al., 2016; Fokkens et al., 2020b).
As a retrospective study, there are several intrinsic
limitations to consider. For example, limited data was available
in some medical records, including previous medical history,
preoperative and postoperative SNOT-22 scores, adverse effects
of topical medication, and culturing method. Both groups in our
study met the previously established MCID for SNOT-22 but it
is difﬁcult to discern how much surgery alone inﬂuenced the
symptom change (Hopkins et al., 2009; Chowdhury et al., 2017).
Additionally, the use of oral antibiotic therapy could confound
the results of our study. We did perform a linear regression to
evaluate its impact among the INCS and topical antibiotic group
but were unable to complete this analysis within the INCS only
group because all patients received an oral antibiotic
regimen postoperatively.
This is a retrospective review focused on the results of medical
intervention. Based on the construct of the study, we must
consider that results may be altered by the lack of patient
compliance, which was not documented in the chart.
Additionally, because of the retrospective nature of our study, a
large number of patients without complete SNOT-22 and LKS
data had to be excluded. We are aware that our limited number of
patients may have obscured a difference in the SNOT-22
outcomes; further studies with a larger sample will lead to a
greater statistical power to conﬁrm our ﬁndings. Given that our
study looked at a unique population of patients, those with AERD,
further studies to examine if these results are similar in nonAERD patients with nasal polyps are needed. There are limitations
in assessing the results of the outcome variables due to the
potential for observer bias in reporting the endoscopic LKS and
confounding results related to the known beneﬁts of ESS and
INCS on symptom scores. Finally, longer follow-up could help to
evaluate the recurrence of nasal polyps and sinus symptoms, as
well as sustained long-term improvement in endoscopic ﬁndings.

with AERD and perioperative positive sinonasal cultures. The
results of this study indicate that in AERD patients, the addition
of culture-directed topical antibiotic irrigation in the immediate
postoperative period leads to a statistically signiﬁcant short-term
improvement in LKS compared to those treated with nasal
steroid irrigation alone. However, our study did not ﬁnd a
signiﬁcant improvement in patient-reported symptoms
measured by SNOT-22 when topical antibiotics were added to
the postoperative treatment regimen compared to INCS alone.
The use of topical antibiotics in CRS remains controversial.
Clinicians continue to use topical antibiotics in patients with
recalcitrant sinus disease, and based on our ﬁndings, there is a
potential beneﬁt with combined therapy for those patients with a
high risk for recalcitrant disease, including those with AERD.
However, the most recent ICAR statement on rhinosinusitis and
EPOS2020 have recommended against its routine use among
CRSwNP patients (Orlandi et al., 2016; Fokkens et al., 2020a).
Their recommendation was based on a few randomized
controlled trials (RCTs), which each used a different drug
delivery system and did not look speciﬁcally at AERD patients
(Sykes et al., 1986; Desrosiers and Salas-Prato, 2001; Videler
et al., 2008; Shikani et al., 2013; Bonﬁls et al., 2015). Only one
RCT has analyzed the effect of topical antibiotic irrigations postESS (Jervis-Bardy et al., 2012; Orlandi et al., 2016; Fokkens et al.,
2020a). They evaluated 25 patients with a documented S. aureus
infection who received mupirocin nasal irrigations or saline
irrigations for one month. Although they reported no
signiﬁcant changes in the SNOT-22 over time, they did note
an immediate change of 4 points in the LKS after completing
topical mupirocin rinses (Jervis-Bardy et al., 2012). This
endoscopic improvement was not sustained after 2 to 6
months, however (Jervis-Bardy et al., 2012). Our results
correlate with these ﬁndings as well as those from several
retrospective studies (Orlandi et al., 2016; Lee and Davis,
2016). Our study does differ from previous studies, because we
found that the improvement in LKS in the patients treated with
topical antibiotics and INCS was sustained over a 6-month
period of time. This observation was conﬁrmed by the linear
regression model which noted an association between the use of
topical antibiotics and improved LKS at 4-weeks and 4-6 months
after ESS. This may be explained by the concurrent and extended
therapy with INCS after the topical antibiotics regimen was
completed or the potential eradication of bioﬁlms.
Bacterial bioﬁlms have been associated with recalcitrant CRS
(Singhal et al., 2010). Staphylococcus aureus and Pseudomonas
are the most commonly isolated bacteria in patients with CRS.
They are also considered bioﬁlm-producer microorganisms,
which can evade both the innate and adaptive immune
response and exacerbate local inﬂammation responses
(Kingdom and Swain, 2004; Bendouah et al., 2006; Zhang
et al., 2015). Additionally, they are associated with recurrent
infection after surgical or medical therapy due to their ability to
elude standard antibiotic therapy and release bacteria in a
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editing. DL: Study design, manuscript writing, and editing. OO:
Study design, manuscript writing, and editing. RA: Statistical
analysis, manuscript writing. JS: Study design, manuscript
writing, and editing. EO’B: Study design, manuscript writing,
and editing. AD: Study design and conceptualization, statistical
analysis, manuscript writing, and editing. All authors
contributed to the article and approved the submitted version.

Conclusion
Our study suggests that in AERD patients with a positive
perioperative bacterial infection, the addition of topical antibiotics
irrigation to maintenance topical corticosteroids irrigation in the
postoperative period provides short improvement in endoscopic
scores. However, combination topical therapy has no effect on
patient-reported postoperative SNOT-22, showing discordance
between observed objective and patient-reported subjective ﬁndings.
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